Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study
Blood (2020) 136 (Supplement 1): 48–49.
Currently there are no citedby results. Try again later.
